- Home
- RADX
RADX
RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
as 02-05-2025 9:50am EST
Stocks
| Founded: | 2021 | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 117.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.55 - $50.82 | Next Earning Date: | 02-26-2025 |
| Revenue: | $1,306,729 | Revenue Growth: | -68.46% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD News
RADX Breaking Stock News: Dive into RADX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement
GlobeNewswire
a month ago
Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia
GlobeNewswire
2 months ago
RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
Share on Social Networks:
Disclaimer
The information presented on this page, "RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.